Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

This study has been completed.
Information provided by:
Immutep S.A. Identifier:
First received: July 7, 2006
Last updated: January 6, 2010
Last verified: January 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):